Financial results
Performance
Five years of steady growth: from 2020 to 2024 production value increased from €8.4M to €11.7M with 8.6% CAGR.
€11.7M
Production Value 2024
vs €8.4M in 2020
8.6%
CAGR 2020-2024
Steady growth
€1.7M
EBITDA 2024
vs €0.5M in 2020
14.8%
EBITDA Margin 2024
Continuous improvement
Growth Drivers
The group attributes growth to entry into new markets and the growing success of key products, in particular ChemoMaker® (revenues from €120k in 2022 to €760k in 2024) and the expansion of the orphan drugs division (12+ tenders awarded).
The improvement in EBITDA margin — from €0.5M (6%) to €1.7M (14.8%) — demonstrates a continuous improvement in operational efficiency and industrial synergies between the various group companies.
Evolution 2020–2024
Partners & Clients
